Pre-made Gemtuzumab benchmark antibody ( Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-p67/SIGLEC3/SIGLEC-3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Gemtuzumab biosimilar, Whole mAb ADC, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-239-1mg	1mg	Inquiry
GMP-Bios-ab-239-10mg	10mg	Inquiry
GMP-Bios-ab-239-100mg	100mg	Inquiry
GMP-Bios-ab-239-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gemtuzumab biosimilar, Whole mAb ADC, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody
INN Name	Gemtuzumab
Target	CD33
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	UCB;Celgene Corporation;Pfizer;University of California San Diego
Conditions Approved	Acute myeloid leukaemia
Conditions Active	na
Conditions Discontinued	na
Development Tech	na